<DOC>
	<DOCNO>NCT01927978</DOCNO>
	<brief_summary>This study aim evaluate effectiveness 18F-FDG PET initial staging , therapy planning , therapeutic response monitoring esophageal cancer patient . Purpose : 1 . The incremental staging information use 18F-FDG PET 2 . The impact PET result patient ' subsequent therapy planning 3 . To compare treatment response use RECIST criterion FDG PET result .</brief_summary>
	<brief_title>Using `` PET Response Criteria Solid Tumors ( PERCIST ) '' Evaluating Response Neoadjuvant Chemoradiotherpy Esophageal Cancer</brief_title>
	<detailed_description>Background : Esophageal cancer one lead malignancy Taiwan . Accuracy tumor stag direct appropriate therapy planning provide prognostic implication . Positron emission tomography ( PET ) [ 18F ] -fluoro-2-deoxy-D-glucose ( FDG ) show well N stag prognostic stratification ability conventional imaging modality , endoscopic ultrasonography ( EUS ) CT. Purpose : This study aim evaluate effectiveness 18F-FDG PET initial staging , therapy planning , therapeutic response monitoring esophageal cancer patient . Method : Patients pathological proven esophageal cancer , age 20-90 year-old , include study . Each patient receive baseline PET study . For patient receive pre-operative CCRT , another PET perform 1-4 week completion CCRT . Primary outcome : 1 . The incremental staging information use 18F-FDG PET 2 . The impact PET result patient ' subsequent therapy planning 3 . To compare treatment response use RECIST criterion FDG PET result . Secondary outcome : To correlate PET response rate patient ' disease free survival overall survival .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Ageï¼š2090 year old 2 . Histological prove esophageal cancer 3 . ECOG performance status 02 4. write informed consent sign 1. prior chemotherapy treatment systemic anticancer agent ( ) 2. pregnant intend pregnant 3. malignancy know 4. concurrent cancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>18F-FDG PET</keyword>
	<keyword>stag</keyword>
	<keyword>therapy planning</keyword>
	<keyword>therapy response monitoring</keyword>
	<keyword>prognosis</keyword>
</DOC>